Clinical Trials Browser

Phase 1/2 × Unknown × Clear all

NCT01885702 2025-04-04

Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT06250244 2024-12-11

177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Unknown

Metastatic Castration-resistant Prostate Cancer

NCT05830097 2024-08-26

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT05832892 2024-06-14

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT03275493 2024-05-28

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04029181 2024-05-03

ImmunoPET With an Anti-CD8 Imaging Agent

Phase 1/2 Unknown

Neoplasm Metastasis

NCT06395337 2024-05-02

MIRCA & MIPAC

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms, Rectal Neoplasms

NCT06394791 2024-05-01

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Phase 1/2 Unknown

Gastrointestinal

Left-sided Colorectal Cancer Complicating Acute Obstruction

NCT05804526 2024-04-30

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumours

NCT05458544 2024-04-29

LUCIDA

Phase 1/2 Unknown

Metastatic Castration-resistant Prostate Cancer

NCT04499339 2024-04-25

A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT05865925 2024-04-25

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumors

NCT06384235 2024-04-25

Phase II Clinical Study of LTC004 in Patients With mCRC

Phase 1/2 Unknown

Locally Advanced or Metastatic CRC

NCT06384248 2024-04-25

Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Phase 1/2 Unknown

Sarcoma

NCT06379399 2024-04-23

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Phase 1/2 Unknown

Gastrointestinal

Colorectal Cancer Metastatic

NCT06030622 2024-04-19

C3

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT05240131 2024-04-12

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05519293 2024-04-11

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05552781 2024-04-11

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06308406 2024-04-11

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Phase 1/2 Unknown

Ovarian Neoplasms

NCT04469127 2024-04-10

Heroine01

Phase 1/2 Unknown

Breast Neoplasms

NCT04573192 2024-04-08

GLIOSTAR

Phase 1/2 Unknown

Glioblastoma

NCT05064618 2024-04-04

MIKE-1

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT04487756 2024-04-03

VENEZO-LUNG

Phase 1/2 Unknown

Small Cell Lung Carcinoma

NCT06328387 2024-03-25

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT03024489 2024-03-15

Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

Phase 1/2 Unknown

Head and Neck Neoplasms

NCT04903873 2024-03-15

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Phase 1/2 Unknown

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Prostatic Neoplasms

NCT03975907 2024-03-12

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Phase 1/2 Unknown

Multiple Myeloma

NCT05111860 2024-03-07

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Phase 1/2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT04601584 2024-03-06

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05370547 2024-03-06

Chidamide Bridging for CAR-T Therapy

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

NCT06237413 2024-03-06

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT04780217 2024-03-04

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Phase 1/2 Unknown

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06106139 2024-03-04

Ketogenic Diet Improves Thrombocytopenia in Cancer Patients

Phase 1/2 Unknown

Ketogenic Diet

NCT03643549 2024-02-29

BORTEM-17

Phase 1/2 Unknown

Glioblastoma, Recurrence

NCT04330820 2024-02-28

RELAX

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05033925 2024-02-28

Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients

Phase 1/2 Unknown

Breast Neoplasms, Neoplasms

NCT06279767 2024-02-28

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

Phase 1/2 Unknown

Glioblastoma, Neoplasms

NCT03576378 2024-02-26

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Phase 1/2 Unknown

Hodgkin Disease

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT05575804 2024-02-26

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Advanced/ Metastatic Her-2 Positive Breast Cancer

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT04934514 2024-02-20

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT05991518 2024-02-20

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

Phase 1/2 Unknown

HER2 Gene Mutation

NCT02730923 2024-02-13

VICTORIA

Phase 1/2 Unknown

Carcinoma, Endometrial Neoplasms

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT04984668 2024-02-09

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT06074029 2024-02-08

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05358379 2024-02-07

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1/2 Unknown

Lymphoma